Ormona® SI and Ormona® RC—New Nutraceuticals with Geranylgeraniol, Tocotrienols, Anthocyanins, and Isoflavones—Decrease High-Fat Diet-Induced Dyslipidemia in Wistar Rats

Dyslipidemia is a metabolic condition linked to increased morbidity. This study aimed to evaluate the effect of two new nutraceuticals derived from annatto (Bixa orellana), açaí (Euterpe oleracea), and soybean germ or red clover isoflavones (Trifolium pratense) against high-fat-induced dyslipidemia in female Wistar rats. The formulations were assessed through GC-MS and HPLC-UV/Vis. Next, female Wistar rats received daily administrations of coconut oil and were treated with Ormona® SI (OSI), Ormona® RC (ORC), soybean germ (SG), simvastatin (simv.), simvastatin + Ormona® SI (simv. + OSI), or only distilled water (control). Biochemical tests were performed using the animals’ blood, and their arteries were screened for atheroma formation. The results show abnormal TC, TG, LDL, and HDL levels caused by the high-fat diet, increased glucose levels, hepatotoxicity, nephrotoxicity, and atherogenesis. The nutraceuticals significantly ameliorated all conditions, with results that are similar to the group treated with simvastatin. Notably, the groups treated with either Ormona® or simvastatin + Ormona® had better liver protection than those treated only with SG or simvastatin; additionally, the nutraceuticals could prevent atherogenesis, unlike SG. The results indicate a high efficacy of the nutraceuticals in preventing dyslipidemia and its complications.